Comments
Loading...

10x Genomics Analyst Ratings

TXGNASDAQ
Logo brought to you by Benzinga Data
$8.86
0.273.14%
At close: -
$9.00
0.141.58%
After Hours: 7:41 PM EDT
Consensus Rating1
Neutral
Highest Price Target1
$60.00
Lowest Price Target1
$6.50
Consensus Price Target1
$23.79

10x Genomics Analyst Ratings and Price Targets | NASDAQ:TXG | Benzinga

10x Genomics Inc has a consensus price target of $23.79 based on the ratings of 20 analysts. The high is $60 issued by Goldman Sachs on July 14, 2022. The low is $6.5 issued by Goldman Sachs on May 12, 2025. The 3 most-recent analyst ratings were released by Morgan Stanley, Stephens & Co., and UBS on May 19, 2025, May 15, 2025, and May 13, 2025, respectively. With an average price target of $14.67 between Morgan Stanley, Stephens & Co., and UBS, there's an implied 62.96% upside for 10x Genomics Inc from these most-recent analyst ratings.

Analyst Trends and Forecast
1
Jan
6
3
Feb
1
Mar
1
Apr
3
2
1
May
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
3.4
Hold
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

Morgan Stanley
Stephens & Co.
UBS
Goldman Sachs
Canaccord Genuity

1calculated from analyst ratings

Analyst Ratings for 10x Genomics

Buy NowGet Alert
05/19/2025Buy Now100%Morgan Stanley
Tejas Savant49%
$26 → $18MaintainsOverweightGet Alert
05/15/2025Buy Now55.56%Stephens & Co.
Mason Carrico38%
$14 → $14ReiteratesOverweight → OverweightGet Alert
05/13/2025Buy Now33.33%UBS
Dan Leonard54%
$14 → $12MaintainsNeutralGet Alert
05/12/2025Buy Now-27.78%Goldman Sachs
Matthew Sykes62%
$7.5 → $6.5MaintainsSellGet Alert
05/12/2025Buy Now66.67%Canaccord Genuity
Kyle Mikson36%
$18 → $15MaintainsBuyGet Alert
05/09/2025Buy Now—JP Morgan
Rachel Vatnsdal64%
$12 → $9MaintainsNeutralGet Alert
04/10/2025Buy Now33.33%Barclays
Luke Sergott50%
$15 → $12MaintainsOverweightGet Alert
03/04/2025Buy Now66.67%Citigroup
Patrick Donnelly80%
$20 → $15MaintainsBuyGet Alert
02/14/2025Buy Now188.89%Morgan Stanley
Tejas Savant49%
$28 → $26MaintainsOverweightGet Alert
02/14/2025Buy Now66.67%Barclays
Luke Sergott50%
$18 → $15MaintainsOverweightGet Alert
02/13/2025Buy Now100%Canaccord Genuity
Kyle Mikson36%
$20 → $18MaintainsBuyGet Alert
02/13/2025Buy Now122.22%Citigroup
Patrick Donnelly80%
$23 → $20MaintainsBuyGet Alert
02/13/2025Buy Now33.33%JP Morgan
Rachel Vatnsdal64%
$14 → $12MaintainsNeutralGet Alert
02/13/2025Buy Now55.56%UBS
Dan Leonard54%
$20 → $14MaintainsNeutralGet Alert
02/13/2025Buy Now100%Stifel
Daniel Arias78%
$21 → $18MaintainsBuyGet Alert
02/13/2025Buy Now33.33%Leerink Partners
Mike Kratky65%
$25 → $12DowngradeOutperform → Market PerformGet Alert
02/10/2025Buy Now100%Barclays
Luke Sergott50%
$19 → $18MaintainsOverweightGet Alert
01/13/2025Buy Now211.11%Morgan Stanley
Tejas Savant49%
$30 → $28MaintainsOverweightGet Alert
11/01/2024Buy Now111.11%Barclays
Luke Sergott50%
$21 → $19MaintainsOverweightGet Alert
10/30/2024Buy Now155.56%Citigroup
Patrick Donnelly80%
$35 → $23MaintainsBuyGet Alert
10/30/2024Buy Now55.56%Goldman Sachs
Matthew Sykes62%
$16 → $14MaintainsSellGet Alert
10/30/2024Buy Now55.56%JP Morgan
Rachel Vatnsdal64%
$20 → $14MaintainsNeutralGet Alert
10/30/2024Buy Now122.22%UBS
Dan Leonard54%
$25 → $20MaintainsNeutralGet Alert
10/15/2024Buy Now133.33%Barclays
Luke Sergott50%
$24 → $21MaintainsOverweightGet Alert
10/10/2024Buy Now233.33%Stephens & Co.
Mason Carrico38%
$30 → $30ReiteratesOverweight → OverweightGet Alert
10/10/2024Buy Now122.22%Canaccord Genuity
Kyle Mikson36%
$32 → $20MaintainsBuyGet Alert
09/04/2024Buy Now233.33%Stephens & Co.
Mason Carrico38%
$30 → $30ReiteratesOverweight → OverweightGet Alert
09/03/2024Buy Now288.89%Leerink Partners
Mike Kratky65%
→ $35Initiates → OutperformGet Alert
08/13/2024Buy Now177.78%UBS
Dan Leonard54%
$30 → $25MaintainsNeutralGet Alert
08/13/2024Buy Now411.11%Morgan Stanley
Tejas Savant49%
$50 → $46MaintainsOverweightGet Alert
07/23/2024Buy Now255.56%Canaccord Genuity
Kyle Mikson36%
$50 → $32MaintainsBuyGet Alert
07/22/2024Buy Now166.67%Jefferies
Tycho Peterson82%
$24 → $24UpgradeHold → BuyGet Alert
07/18/2024Buy Now177.78%B of A Securities
Derik De Bruin84%
$36 → $25MaintainsNeutralGet Alert
07/18/2024Buy Now122.22%JP Morgan
Rachel Vatnsdal64%
$40 → $20DowngradeOverweight → NeutralGet Alert
07/16/2024Buy Now177.78%Stifel
Daniel Arias78%
$53 → $25MaintainsBuyGet Alert
07/10/2024Buy Now177.78%Deutsche Bank
Justin Bowers47%
$55 → $25DowngradeBuy → HoldGet Alert
07/09/2024Buy Now77.78%Goldman Sachs
Matthew Sykes62%
$26 → $16MaintainsSellGet Alert
06/28/2024Buy Now166.67%Barclays
Luke Sergott50%
$36 → $24MaintainsOverweightGet Alert
06/27/2024Buy Now—Wolfe Research
Doug Schenkel71%
—DowngradeOutperform → Peer PerformGet Alert
06/26/2024Buy Now—Guggenheim
Subbu Nambi40%
—DowngradeBuy → NeutralGet Alert
06/25/2024Buy Now—Guggenheim
Subbu Nambi40%
—DowngradeBuy → NeutralGet Alert
06/03/2024Buy Now166.67%Jefferies
Tycho Peterson82%
→ $24Initiates → HoldGet Alert
05/01/2024Buy Now233.33%UBS
Dan Leonard54%
$52 → $30MaintainsNeutralGet Alert
05/01/2024Buy Now300%B of A Securities
Derik De Bruin84%
$45 → $36MaintainsNeutralGet Alert
05/01/2024Buy Now188.89%Goldman Sachs
Matthew Sykes62%
$30 → $26MaintainsSellGet Alert
05/01/2024Buy Now255.56%TD Cowen
Dan Brennan61%
$57 → $32DowngradeBuy → HoldGet Alert
05/01/2024Buy Now488.89%Stifel
Daniel Arias78%
$63 → $53MaintainsBuyGet Alert
04/29/2024Buy Now455.56%Canaccord Genuity
Kyle Mikson36%
$65 → $50MaintainsBuyGet Alert
04/18/2024Buy Now511.11%Deutsche Bank
Justin Bowers47%
$60 → $55MaintainsBuyGet Alert
04/10/2024Buy Now400%Barclays
Luke Sergott50%
$55 → $45MaintainsOverweightGet Alert
02/16/2024Buy Now600%Stifel
Daniel Arias78%
$68 → $63MaintainsBuyGet Alert
01/25/2024Buy Now511.11%Barclays
Luke Sergott50%
$45 → $55MaintainsOverweightGet Alert
12/14/2023Buy Now566.67%Guggenheim
Subbu Nambi40%
→ $60Initiates → BuyGet Alert
12/13/2023Buy Now—Wolfe Research
Doug Schenkel71%
—Initiates → OutperformGet Alert
12/12/2023Buy Now500%B of A Securities
Derik De Bruin84%
$36 → $54UpgradeUnderperform → NeutralGet Alert
09/29/2023Buy Now422.22%Barclays
Luke Sergott50%
$66 → $47MaintainsOverweightGet Alert
09/19/2023Buy Now677.78%Canaccord Genuity
Kyle Mikson36%
→ $70ReiteratesBuy → BuyGet Alert
08/07/2023Buy Now622.22%Morgan Stanley
Tejas Savant49%
$65 → $65ReiteratesOverweight → OverweightGet Alert
08/04/2023Buy Now633.33%Barclays
Luke Sergott50%
$65 → $66MaintainsOverweightGet Alert
08/04/2023Buy Now733.33%Citigroup
Patrick Donnelly80%
$65 → $75MaintainsBuyGet Alert
07/13/2023Buy Now233.33%Goldman Sachs
Matthew Sykes62%
$25 → $30MaintainsSellGet Alert
05/18/2023Buy Now622.22%Stephens & Co.
Mason Carrico38%
→ $65ReiteratesOverweight → OverweightGet Alert
05/10/2023Buy Now622.22%Barclays
Luke Sergott50%
→ $65Initiates → OverweightGet Alert
05/04/2023Buy Now655.56%Stifel
Daniel Arias78%
$57 → $68MaintainsBuyGet Alert
05/04/2023Buy Now633.33%TD Cowen
Dan Brennan61%
$62 → $66MaintainsOutperformGet Alert
05/04/2023Buy Now622.22%Canaccord Genuity
Kyle Mikson36%
$58 → $65MaintainsBuyGet Alert
05/04/2023Buy Now622.22%Stephens & Co.
Mason Carrico38%
→ $65Reiterates → OverweightGet Alert
03/31/2023Buy Now622.22%Stephens & Co.
Mason Carrico38%
→ $65Initiates → OverweightGet Alert
02/16/2023Buy Now622.22%Morgan Stanley
Tejas Savant49%
$64 → $65MaintainsOverweightGet Alert
02/16/2023Buy Now544.44%Canaccord Genuity
Kyle Mikson36%
$55 → $58MaintainsBuyGet Alert
02/16/2023Buy Now533.33%Cowen & Co.
Dan Brennan61%
$52 → $57MaintainsOutperformGet Alert
02/02/2023Buy Now455.56%UBS
John Sourbeer30%
→ $50Initiates → NeutralGet Alert
12/14/2022Buy Now455.56%Deutsche Bank
Justin Bowers47%
→ $50Initiates → BuyGet Alert
11/04/2022Buy Now611.11%Morgan Stanley
Tejas Savant49%
$70 → $64MaintainsOverweightGet Alert
10/13/2022Buy Now177.78%Goldman Sachs
Matthew Sykes62%
$35 → $25MaintainsSellGet Alert
08/18/2022Buy Now288.89%Goldman Sachs
Matthew Sykes62%
$55 → $35DowngradeNeutral → SellGet Alert
08/10/2022Buy Now677.78%Morgan Stanley
Tejas Savant49%
$100 → $70MaintainsOverweightGet Alert
07/15/2022Buy Now455.56%Cowen & Co.
Dan Brennan61%
$90 → $50MaintainsOutperformGet Alert
07/15/2022Buy Now288.89%B of A Securities
Derik De Bruin84%
$80 → $35DowngradeNeutral → UnderperformGet Alert
07/15/2022Buy Now—William Blair
Brian Weinstein28%
—DowngradeOutperform → Market PerformGet Alert
07/14/2022Buy Now566.67%Goldman Sachs
Amit Hazan56%
$80 → $60MaintainsNeutralGet Alert

FAQ

Q

What is the target price for 10x Genomics (TXG) stock?

A

The latest price target for 10x Genomics (NASDAQ:TXG) was reported by Morgan Stanley on May 19, 2025. The analyst firm set a price target for $18.00 expecting TXG to rise to within 12 months (a possible 100.00% upside). 42 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for 10x Genomics (TXG)?

A

The latest analyst rating for 10x Genomics (NASDAQ:TXG) was provided by Morgan Stanley, and 10x Genomics maintained their overweight rating.

Q

When was the last upgrade for 10x Genomics (TXG)?

A

The last upgrade for 10x Genomics Inc happened on July 22, 2024 when Jefferies raised their price target to $24. Jefferies previously had a hold for 10x Genomics Inc.

Q

When was the last downgrade for 10x Genomics (TXG)?

A

The last downgrade for 10x Genomics Inc happened on February 13, 2025 when Leerink Partners changed their price target from $25 to $12 for 10x Genomics Inc.

Q

When is the next analyst rating going to be posted or updated for 10x Genomics (TXG)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of 10x Genomics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for 10x Genomics was filed on May 19, 2025 so you should expect the next rating to be made available sometime around May 19, 2026.

Q

Is the Analyst Rating 10x Genomics (TXG) correct?

A

While ratings are subjective and will change, the latest 10x Genomics (TXG) rating was a maintained with a price target of $26.00 to $18.00. The current price 10x Genomics (TXG) is trading at is $9.00, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch